The Rishena CNS system is composed of?Implantable Rechargeable Neurostimulator, Implantable Neurostimulation Lead, Implantable Neurostimulation Extension, Combined Programmer and Recharger and other components. It integrates a number of innovative technologies such as 8-contact leads, directional leads, perceptibility, automatic position sensing, visual remote programming, and wireless charging, reaching the international leading level.

PERCEPTIBLE, DYNAMICALLY COLLECTING LOCAL FIELD POTENTIAL (LFP)
Collect local field potential (LFP) in real time, and the collected LFP signal can be transmitted to the patient end/doctor end APP through Bluetooth.
Doctors can remotely view the patient's LFP signal and carry out local field potential analysis to understand the patient's condition and adjust the treatment plan.
Up to 16 channels stimulation and 8 channels signal acquisition.
?
COMPREHENSIVE LEAD TYPE, SUITABLE FOR DIFFERENT CLINICAL APPLICATION SCENARIOS
Connect four 4-contact leads to cover more nuclei.
Connect two 8-contact leads to expand the stimulation range.
Directional Lead
AUTOMATIC POSTURE SENSING
DIVERSIFIED STIMULATION MODES
It supports Normal mode, Timer mode, Periodic mode and other stimulation modes to meet the clinical personalized treatment needs.
Rishena's registered clinical trial* first verified the efficacy of the closed-loop mode in the treatment of Parkinson's disease. Using the self-developed closed-loop Parkinson's disease algorithm, patients have gained a good experience. The research results have been published in Neuromodulation, the official journal of the International Neuromodulation Society. The study shows that:
Assessment at 360 days postoperatively revealed:
? ? ? ? (1)Compared with baseline, both aDBS and cDBS significantly improved motor and non-motor symptoms in patients with Parkinson's? ? ? ? ? ? ? ? ? ? ? ?disease (there was no statistical difference in MDS-UPDRS III scores between the two groups)
? ? ? ?(2)The aDBS group showed statistical superiority in:
? ? ? ? ? ?MDS-UPDRS II?improvement rate:57.29% vs 33.02%(p=0.022) ?????
? ? ? ? ? ?MDS-UPDRS IV?improvement rate:59.83% vs 36.69(p=0.026)
? ? ? ? ? ?PDQ-39?improvement rate:56.91% vs 27.37%(p=0.031)
? ? ? ? ? ?LEDD?improvement rate:53.35%vs 29.16%(p=0.002)


VISUAL REMOTE PROGRAM CONTROL TECHNOLOGY
SUPPORTING COMPREHENSIVE SURGICAL SOLUTIONS
